{
    "organizations": [],
    "uuid": "2f2a3afef11b9edc63b4448d7db8856d49e1c1c0",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-oncomed-pharmaceuticals-reports-q4/brief-oncomed-pharmaceuticals-reports-q4-earnings-per-share-0-25-idUSFWN1QQ0ZG",
    "ord_in_thread": 0,
    "title": "BRIEF-Oncomed Pharmaceuticals Reports Q4 Earnings Per Share $0.25",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "March 8 (Reuters) - Oncomed Pharmaceuticals Inc:\n* Q4 REVENUE $20.6 MILLION VERSUS $6.2 MILLION * ONCOMED PHARMACEUTICALS - CURRENT CASH IS ESTIMATED TO BE SUFFICIENT TO FUND OPERATIONS THROUGH AT LEAST Q3 OF 2019\n* ONCOMED PHARMACEUTICALS SAYS ESTIMATES 2018 OPERATING CASH BURN TO BE ABOUT $55 MILLION, BEFORE CONSIDERING POTENTIAL MILESTONES/OPT-INS - SEC FILING Source text: ( bit.ly/2Fm92Fh ) Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles.",
    "published": "2018-03-09T05:42:00.000+02:00",
    "crawled": "2018-03-09T14:30:45.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "march",
        "reuters",
        "oncomed",
        "pharmaceutical",
        "inc",
        "q4",
        "revenue",
        "million",
        "versus",
        "million",
        "oncomed",
        "pharmaceutical",
        "current",
        "cash",
        "estimated",
        "sufficient",
        "fund",
        "operation",
        "least",
        "q3",
        "oncomed",
        "pharmaceutical",
        "say",
        "estimate",
        "operating",
        "cash",
        "burn",
        "million",
        "considering",
        "potential",
        "sec",
        "filing",
        "source",
        "text",
        "company",
        "coverage",
        "standard",
        "thomson",
        "reuters",
        "trust",
        "principle"
    ]
}